Evidence map›Paper›PMID 37298377›Full record

ReviewInternational journal of molecular sciences2023

Impact of Probiotics on the Prevention and Treatment of Gastrointestinal Diseases in the Pediatric Population.

José Antonio García-Santos, Ana Nieto-Ruiz, María García-Ricobaraza, Tomás Cerdó, Cristina Campoy

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Placebo-resistant gut bacteria:Frontiers in cellular and infection microbiology · 2024
    Trial
  2. Health benefits ofFrontiers in microbiology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

José Antonio García-SantosDepartment of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
Ana Nieto-RuizDepartment of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.ORCID 0000-0002-4303-6228
María García-RicobarazaDepartment of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
Tomás CerdóDepartment of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.ORCID 0000-0002-5653-4314
Cristina CampoyDepartment of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.ORCID 0000-0002-9860-6785
Universidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high prevalence of gastrointestinal disorders (GIDs) in infants and children, especially those categorized as functional GIDs (FGIDs), insufficient knowledge about their pathophysiology has limited both symptomatic diagnosis and the development of optimal therapies. Recent advances in the field of probiotics have made their potential use as an interesting therapeutic and preventive strategy against these disorders possible, but further efforts are still needed. In fact, there is great controversy surrounding this topic, generated by the high variety of potential probiotics strains with plausible therapeutic utility, the lack of consensus in their use as well as the few comparative studies available on probiotics that record their efficacy. Taking into account these limitations, and in the absence of clear guidelines about the dose and timeframe for successful probiotic therapy, our review aimed to evaluate current studies on potential use of probiotics for the prevention and treatment of the most common FGIDs and GIDs in the pediatric population. Furthermore, matters referring to know major action pathways and key safety recommendations for probiotic administration proposed by major pediatric health agencies shall also be discussed.

Indexed as

Gastrointestinal DiseasesProbioticsChildConsensusHumansInfantchildrenfunctional gastrointestinal disordersgastrointestinal disordersgut microbiotainfantsprobiotics

Identifiers

PMID37298377
PMCPMC10253478
OpenAlexW4378716742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.